The company historically manufactured copper and brass capillary tubes and components for refrigeration and air conditioning systems, but it has recently ceased all manufacturing operations and sold its core physical assets.
The company possesses no competitive advantage, as evidenced by the total cessation of operations, the disposal of its plant and machinery, and the write-off of its entire inventory as obsolete.
Capital allocation has been destructive, characterized by chronic operating losses, the eventual liquidation of the business's productive assets, and the distribution of value through asset sales rather than profitable reinvestment.
The investment collapsed as the company transitioned from a failed manufacturer into a hollow shell. Having already liquidated its plant, machinery, and land, the remaining cash was likely drained by administrative overhead and unresolved contingent liabilities from past export failures. The speculative premium evaporated when the market realized there was no operating business left to pivot, leaving shareholders with a non-functional entity that lacks even a basic website or compliant regulatory standing.
RichFakir rates Mardia Samyoung Capillary Tubes Company Ltd's business quality as mediocre — 43/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mardia Samyoung Capillary Tubes Company Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mardia Samyoung Capillary Tubes Company Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mardia Samyoung Capillary Tubes Company Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →